Howard Scher

Howard Scher has led pivotal clinical trials validating CTC enumeration as a prognostic and predictive biomarker in metastatic castration-resistant prostate cancer, including studies that supported FDA clearance of the CellSearch CTC system. His work demonstrating that CTC count changes during treatment predict survival has established CTCs as a clinical endpoint accepted by regulatory agencies. He leads precision medicine trials using CTC molecular profiling to guide treatment selection in advanced prostate cancer.